RxDoctor Payments Data

Lutz Pierre, PA

Physician Assistant · Gastonia, NCNPI 1598509150

Payments from drug & device makers

$6,420in general payments, 2019–2025

Across 313 payments — averaging $20.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$969
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$684
  • Neurocrine Biosciences, Inc.$626
  • Vanda Pharmaceuticals Inc.$517
  • Johnson & Johnson$452
  • Otsuka America Pharmaceutical, Inc.$434
  • plus $3K from 14 others

What the payments were for

  • Food & beverage$6,20797%
  • Education$2133%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,420 in reported general payments places this provider in the 90th percentile of 7,441 physician assistant providers in North Carolina.

See all physician assistant providers in North Carolina

Medicare billing

Part B allowed, 2024
$10,763
Medicare patients
60
Services billed
151

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl42$61,627
RexultiBrexpiprazole39$53,189
Austedo XrDeutetrabenazine11$49,442
FanaptIloperidone12$30,542
TrintellixVortioxetine Hydrobromide27$13,227
BelsomraSuvorexant13$5,438
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl44$4,943
VyvanseLisdexamfetamine Dimesylate11$4,364
Lisdexamfetamine Dimesylate16$3,714
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine97$3,176
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine47$2,891
Bupropion XlBupropion Hcl79$2,885
Vilazodone Hcl24$2,330
Buprenorphine Hcl15$1,787
Doxepin Hcl68$1,712

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$321$61,62742 claims
Otsuka America Pharmaceutical, Inc.Rexulti$434$53,18939 claims
Teva Pharmaceuticals USA, Inc.Austedo Xr$969$49,44211 claims
Vanda Pharmaceuticals Inc.Fanapt$517$30,54212 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$119$17,59138 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,441 physician assistant providers in North Carolina.

Other physician assistant in Gastonia

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →